EarliPoint Health

EarliPoint Health operates at the intersection of medical devices, health diagnostics, biometrics, and digital health. Its point of differentiation is an FDA-cleared eye-tracking system that quantifies social visual engagement and supplies standardized information to complement clinicians’ autism evaluations. The company frames the technology for both diagnosis and ongoing assessment, while its network and research programs aim to support validation and integration into provider workflows. This creates a narrower, measurement-focused position than general-purpose digital health software: the central product is a clinical assessment device and associated evaluation, not simply a care-delivery platform. The disclosed $41 million across a 2022 Series A and 2024 Series B provides evidence of venture financing for this specialized approach, but does not establish market share or widespread adoption. Its differentiation will depend on clinical utility, workflow fit, provider access, and whether objective measurements add actionable value alongside established clinical assessment methods.

EarliPoint’s disclosed financing history shows two substantial funding steps: a $19.5 million Series A on Feb 18, 2022, led by Bernie Marcus, followed by a $21.5 million Series B on Apr 2, 2024, led by Nexus NeuroTech Ventures and Venture Investors Health Fund. Together, the rounds total $41 million. The clearest later inflection point is Project ALIGN, announced on Jul 27, 2026 with seven autism therapy providers. The collaboration extends the company’s strategy beyond supplying an assessment device toward implementation and shared measurement practices across provider organizations. That could support broader workflow integration, although adoption or clinical outcomes from the initiative have not been quantified. EarliPoint also offers research and network programs intended to support validation and provider access, and it is hiring an Account Executive to expand the EarliPoint Network. The 2024 financing remains its latest disclosed round in this profile; the intervening time to the 2026 partnership makes execution and demonstrated provider uptake important markers for assessing the next phase.